Owlstone Medical
Developing a breathalyzer for disease for the early detection of cancer, inflammatory and infectious disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | $2.3m | Grant | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (14 %) | 49 % | 8 % | 9 % | (60 %) | 30 % | 29 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (339 %) | (342 %) | (340 %) | (344 %) | (1268 %) | (995 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (295 %) | (299 %) | (330 %) | (341 %) | (1120 %) | (926 %) | (864 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 219 % | 254 % | 818 % | 708 % | - |
Source: Company filings or news article
Related Content
Owlstone Medical is a health technology startup that operates in the medical diagnostics market. The company specializes in developing non-invasive diagnostic tests using breath biopsy technology. This technology analyzes volatile organic compounds (VOCs) in a patient's breath to detect diseases such as lung cancer at an early stage. The company's primary clients are healthcare providers and research organizations worldwide.
Owlstone Medical's business model revolves around the development and sale of its breath biopsy products and services. The company offers a range of products for breath biopsy research, including the Breath Biopsy OMNI, an advanced solution for volatile metabolite analysis in breath, and the ReCIVA Breath Sampler, a tool for reliable and reproducible breath sample collection. These products are used in clinical trials and research labs to bring VOC biomarker research in-house.
In addition to selling products, Owlstone Medical also offers services such as OMED Health, a service that helps individuals manage their digestive health through at-home breath testing and professional analysis of exhaled gases. The company generates revenue through the sale of its products and services.
Owlstone Medical is making significant strides in the field of early disease detection, as demonstrated by their latest data on the development of a Breath Biopsy test for early detection of lung cancer. The company's innovative approach to medical diagnostics has the potential to revolutionize the healthcare industry by providing non-invasive, accurate, and early detection of various diseases.
Keywords: Owlstone Medical, Breath Biopsy, Non-Invasive Diagnostics, Lung Cancer Detection, Volatile Organic Compounds, Medical Diagnostics Market, Healthcare Providers, Breath Biopsy OMNI, ReCIVA Breath Sampler, OMED Health.
